NYSE:AMRX - Amneal Pharmaceuticals Stock Price, Forecast & News

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMRX stock has decreased by 5.5% and is now trading at $3.07. View which stocks have been mosted impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Amneal Pharmaceuticals.

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Amneal Pharmaceuticals.

Amneal Pharmaceuticals Inc (NYSE:AMRX) released its earnings results on Wednesday, February, 26th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.05 by $0.03. The firm earned $397 million during the quarter, compared to the consensus estimate of $382.10 million. Amneal Pharmaceuticals had a negative net margin of 22.25% and a positive return on equity of 15.09%. The firm's revenue was down 20.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.33 EPS. View Amneal Pharmaceuticals' earnings history.

Amneal Pharmaceuticals issued an update on its FY20 earnings guidance on Wednesday, February, 26th. The company provided earnings per share (EPS) guidance of 0.45-0.60 for the period, compared to the Thomson Reuters consensus estimate of $0.52. The company issued revenue guidance of 1.875-1.975 billion, compared to the consensus revenue estimate of $1.68 billion.

11 brokers have issued 1-year target prices for Amneal Pharmaceuticals' shares. Their forecasts range from $2.50 to $14.00. On average, they expect Amneal Pharmaceuticals' share price to reach $6.30 in the next year. This suggests a possible upside of 105.2% from the stock's current price. View analysts' price targets for Amneal Pharmaceuticals.

Media coverage about AMRX stock has trended very negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amneal Pharmaceuticals earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAmneal Pharmaceuticals.

Amneal Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 4,390,000 shares, an increase of 20.3% from the February 13th total of 3,650,000 shares. Based on an average daily trading volume, of 2,670,000 shares, the short-interest ratio is presently 1.6 days. Currently, 4.9% of the shares of the stock are short sold. View Amneal Pharmaceuticals' Current Options Chain.

Some companies that are related to Amneal Pharmaceuticals include Evotec (EVTCY), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Global Blood Therapeutics (GBT), Blueprint Medicines (BPMC), FibroGen (FGEN), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Emergent Biosolutions (EBS), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), PPD (SDGR), PTC Therapeutics (PTCT) and Ultragenyx Pharmaceutical (RARE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Canopy Growth (CGC), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX) and NIO (NIO).

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Amneal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (0.76%), Geode Capital Management LLC (0.51%), Bank of New York Mellon Corp (0.44%), Norges Bank (0.36%), Prudential Financial Inc. (0.31%) and Mackay Shields LLC (0.26%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Bryan M Reasons, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Joseph Todisco, Nikita Shah, Paul Bisaro, Paul M Meister, Peter R Terreri, Pradeep Bhadauria and Ted C Nark. View institutional ownership trends for Amneal Pharmaceuticals.

AMRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Spark Investment Management LLC, Strs Ohio, First Trust Advisors LP, Cubist Systematic Strategies LLC, Goldman Sachs Group Inc., UBS Asset Management Americas Inc., and Meeder Asset Management Inc.. View insider buying and selling activity for Amneal Pharmaceuticals.

AMRX stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Bank of New York Mellon Corp, Mackay Shields LLC, Marshall Wace LLP, Bank of America Corp DE, State Street Corp, Nuveen Asset Management LLC, and Geode Capital Management LLC. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Joseph Todisco, Paul Bisaro, Paul M Meister, Pradeep Bhadauria, and Ted C Nark. View insider buying and selling activity for Amneal Pharmaceuticals.

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMRX stock can currently be purchased for approximately $3.07.

Amneal Pharmaceuticals has a market capitalization of $918.62 million and generates $1.63 billion in revenue each year. The company earns $-361,920,000.00 in net income (profit) each year or $0.27 on an earnings per share basis. Amneal Pharmaceuticals employs 5,500 workers across the globe. View additional information about Amneal Pharmaceuticals.

The official website for Amneal Pharmaceuticals is http://www.amneal.com/.

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]